These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effects of the CCK receptor antagonist MK-329 on food intake in pigs. Ebenezer IS; de la Riva C; Baldwin BA Physiol Behav; 1990 Jan; 47(1):145-8. PubMed ID: 2326329 [TBL] [Abstract][Full Text] [Related]
23. Selectivity of cholecystokinin (CCK) receptor antagonists, MK-329 and L-365,260, for axonally-transported CCK binding sites on the rat vagus nerve. Mercer JG; Lawrence CB Neurosci Lett; 1992 Mar; 137(2):229-31. PubMed ID: 1374868 [TBL] [Abstract][Full Text] [Related]
24. The effect of the cholecystokinin receptor antagonist MK-329 on meal-stimulated pancreaticobiliary output in humans. Cantor P; Mortensen PE; Myhre J; Gjorup I; Worning H; Stahl E; Survill TT Gastroenterology; 1992 May; 102(5):1742-51. PubMed ID: 1568584 [TBL] [Abstract][Full Text] [Related]
25. The effect of antagonist of receptors for gastrin, cholecystokinin and bombesin on growth of gastroduodenal mucosa and pancreas. Dembiński A; Warzecha Z; Konturek SJ; Banas M; Cai RZ; Schally AV J Physiol Pharmacol; 1991 Sep; 42(3):263-77. PubMed ID: 1665365 [TBL] [Abstract][Full Text] [Related]
26. Effects of the CCK receptor antagonist L364,718 on pancreatic growth in adult and developing animals. Zucker KA; Adrian TE; Bilchik AJ; Modlin IM Am J Physiol; 1989 Oct; 257(4 Pt 1):G511-6. PubMed ID: 2478030 [TBL] [Abstract][Full Text] [Related]
27. The cholecystokinin antagonist L-364,718 inhibits the action of cholecystokinin but not bombesin on rat pancreatic secretion in vivo. Anderson L; Dockray GJ Eur J Pharmacol; 1988 Feb; 146(2-3):307-11. PubMed ID: 3371402 [TBL] [Abstract][Full Text] [Related]
28. CCK antagonists interact with CCK-B receptors on human small cell lung cancer cells. Staley J; Jensen RT; Moody TW Peptides; 1990; 11(5):1033-6. PubMed ID: 2178246 [TBL] [Abstract][Full Text] [Related]
29. Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260. Hill DR; Woodruff GN Brain Res; 1990 Sep; 526(2):276-83. PubMed ID: 2257485 [TBL] [Abstract][Full Text] [Related]
30. Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. Liddle RA; Gertz BJ; Kanayama S; Beccaria L; Coker LD; Turnbull TA; Morita ET J Clin Invest; 1989 Oct; 84(4):1220-5. PubMed ID: 2794058 [TBL] [Abstract][Full Text] [Related]
32. Effects of endogenous and exogenous cholecystokinin and of infusion with the cholecystokinin antagonist L-364,718 on pancreatic and gastrointestinal growth. Axelson J; Håkanson R; Ihse I; Lilja I; Rehfeld JF; Sundler F Scand J Gastroenterol; 1990 May; 25(5):471-80. PubMed ID: 2359975 [TBL] [Abstract][Full Text] [Related]
33. Effects of high fat diet and cholecystokinin receptor blockade on pancreatic growth and tumor initiation in the hamster. Herrington MK; Permert J; Kazakoff KR; Pour PM; Zuker KA; Bilchik AJ; Adrian TE Carcinogenesis; 1993 May; 14(5):1021-6. PubMed ID: 7684953 [TBL] [Abstract][Full Text] [Related]
34. Characterization of a new diphenylpyrazolidinone cholecystokinin antagonist in vitro isolated rat pancreatic acini. Akiyama T; Tachibana I; Otsuki M Int J Pancreatol; 1993 Oct; 14(2):167-73. PubMed ID: 7506744 [TBL] [Abstract][Full Text] [Related]
35. Importance of cholecystokinin in peptide-YY release in response to pancreatic juice diversion. Guan D; Rivard N; Maouyo D; Gettys TW; Morisset J Regul Pept; 1993 Feb; 43(3):169-76. PubMed ID: 8441822 [TBL] [Abstract][Full Text] [Related]
36. Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey. Graham WC; Hill DR; Woodruff GN; Sambrook MA; Crossman AR Neurosci Lett; 1991 Sep; 131(1):129-34. PubMed ID: 1791971 [TBL] [Abstract][Full Text] [Related]
37. CCK satiety is differentially mediated by high- and low-affinity CCK receptors in mice and rats. Weatherford SC; Laughton WB; Salabarria J; Danho W; Tilley JW; Netterville LA; Schwartz GJ; Moran TH Am J Physiol; 1993 Feb; 264(2 Pt 2):R244-9. PubMed ID: 8447480 [TBL] [Abstract][Full Text] [Related]
38. Gastrin-releasing peptide and cholecystokinin in the regulation of exocrine pancreatic secretion in dogs. Nustede R; Schmidt WE; Lohmann C; Köhler H; Schlemminger R; Schafmayer A Digestion; 1993; 54(2):79-83. PubMed ID: 8319843 [TBL] [Abstract][Full Text] [Related]
39. Effect of CCK antagonist L 364718 on meal-induced pancreatic secretion in rats. O'Rourke MF; Reidelberger RD; Solomon TE Am J Physiol; 1990 Feb; 258(2 Pt 1):G179-84. PubMed ID: 1689547 [TBL] [Abstract][Full Text] [Related]
40. Red kidney bean lectin is a potent cholecystokinin releasing stimulus in the rat inducing pancreatic growth. Herzig KH; Bardocz S; Grant G; Nustede R; Fölsch UR; Pusztai A Gut; 1997 Sep; 41(3):333-8. PubMed ID: 9378388 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]